Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01431300 · ClinicalTrials.gov registry record · NA
Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants
A NA study of Healthy, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01431300 is a NA study of Healthy that has completed, run by Duke University. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01431300, a NA study of Healthy, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images.
Conditions Studied
Interventions
- DRUG gadofosveset
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01431300
The ClinicalTrials.gov registry entry for NCT01431300 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which gadofosveset is the first listed.
NCT01431300 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01431300 about?
NCT01431300 is a clinical study titled "Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants". The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be re...
What is the current status of trial NCT01431300?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2011-08. Estimated completion is 2013-07.
What conditions does trial NCT01431300 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT01431300?
The interventions under investigation include: gadofosveset (DRUG).
Who is sponsoring clinical trial NCT01431300?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01431300 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.